DermaVir, a novel HIV immunisation technology.
Vaccine
; 23(17-18): 2030-4, 2005 Mar 18.
Article
en En
| MEDLINE
| ID: mdl-15755566
ABSTRACT
DermaVir is a novel topical immunisation designed to target Langerhans cells (LC), the epidermal precursors of dendritic cells. LC serve as a vehicle to process and transfer antigens from the skin to T cell areas in the lymphoid organs. The HIV DNA delivered by DermaVir to LC expresses most viral regulatory and structural genes and induces T cell-mediated immune responses with broad specificity. In chronically infected macaques, DermaVir administered with antiretroviral drugs, suppressed viral load rebound after treatment interruption and improved survival. DermaVir is a promising antiretroviral treatment approach with a unique mechanism of action for combination with currently used drugs.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra el SIDA
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Vaccine
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos